NYSE:LH - Laboratory Co. of America Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $276.08
  • Forecasted Upside: 6.56 %
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
$259.09
▼ -1.34 (-0.51%)
1 month | 3 months | 12 months
Get New Laboratory Co. of America Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LH

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$276.08
▲ +6.56% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Laboratory Co. of America in the last 3 months. The average price target is $276.08, with a high forecast of $320.00 and a low forecast of $217.00. The average price target represents a 6.56% upside from the last price of $259.09.

Buy

The current consensus among 11 investment analysts is to buy stock in Laboratory Co. of America. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/24/2019
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/23/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/21/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/19/2020
  • 0 strong buy ratings
  • 14 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/18/2020
  • 0 strong buy ratings
  • 14 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 13 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/17/2021
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/20/2021ArgusBoost Price TargetAverage ➝ Buy$270.00 ➝ $295.00Medium
i
5/12/2021MizuhoBoost Price TargetBuy$267.00 ➝ $310.00Low
i
5/3/2021TruistBoost Price Target$300.00 ➝ $320.00Low
i
5/3/2021CitigroupBoost Price Target$278.00 ➝ $312.00Low
i
5/3/2021Jefferies Financial GroupBoost Price TargetBuy$300.00 ➝ $310.00Low
i
4/14/2021TruistBoost Price Target$280.00 ➝ $300.00High
i
4/14/2021Truist SecuritiesBoost Price TargetAbove Average ➝ Buy$280.00 ➝ $300.00Medium
i
4/1/2021Jefferies Financial GroupReiterated RatingBuyHigh
i
2/12/2021CitigroupBoost Price TargetBuy$257.00 ➝ $278.00Low
i
2/12/2021JPMorgan Chase & Co.Boost Price TargetOverweight$261.00 ➝ $279.00Low
i
2/12/2021MizuhoBoost Price TargetBuy$242.00 ➝ $267.00Low
i
1/29/2021CitigroupBoost Price TargetBuy$249.00 ➝ $257.00Low
i
1/14/2021MizuhoBoost Price TargetBuy$234.00 ➝ $242.00Low
i
1/11/2021ArgusUpgradeHold ➝ Buy$245.00Medium
i
1/8/2021Wolfe ResearchDowngradeOutperform ➝ Peer PerformHigh
i
Rating by Steve Baxter at Wolfe Research
10/28/2020Wells Fargo & CompanyBoost Price TargetOverweight$225.00 ➝ $260.00Low
i
10/28/2020MizuhoBoost Price TargetBuy$215.00 ➝ $234.00Low
i
10/27/2020William BlairReiterated RatingOutperformLow
i
Rating by M. Larew at William Blair
10/14/2020Jefferies Financial GroupBoost Price TargetBuy$183.00 ➝ $230.00Low
i
7/31/2020MizuhoBoost Price TargetBuy$186.00 ➝ $215.00Low
i
7/29/2020Bank of AmericaBoost Price TargetBuy$220.00 ➝ $240.00Medium
i
Rating by Derik De Bruin at Bank of America Co.
7/29/2020SunTrust BanksBoost Price TargetPositive ➝ Buy$220.00 ➝ $240.00Medium
i
7/29/2020Deutsche Bank AktiengesellschaftBoost Price TargetBuy$210.00 ➝ $230.00Medium
i
Rating by Pito Chickering at Deutsche Bank Aktiengesellschaft
7/29/2020CitigroupBoost Price TargetBuy$214.00 ➝ $249.00Medium
i
7/14/2020Bank of AmericaUpgradeNeutral ➝ Buy$194.00 ➝ $220.00High
i
7/13/2020Wolfe ResearchUpgradePeer Perform ➝ Outperform$202.00 ➝ $217.00High
i
Rating by Steve Baxter at Wolfe Research
6/10/2020Wells Fargo & CompanyReiterated RatingBuyMedium
i
6/8/2020Robert W. BairdBoost Price TargetOutperform$199.00 ➝ $219.00Medium
i
6/4/2020JPMorgan Chase & Co.Boost Price TargetOverweight$118.00 ➝ $223.00Medium
i
6/2/2020Deutsche Bank AktiengesellschaftInitiated CoverageBuy$210.00Medium
i
5/21/2020SunTrust BanksBoost Price TargetBuy$200.00 ➝ $220.00Medium
i
5/20/2020Morgan StanleyBoost Price TargetOverweight$241.00 ➝ $244.00Low
i
5/15/2020MizuhoUpgradeNeutral ➝ Buy$158.00 ➝ $186.00Low
i
5/5/2020UBS GroupBoost Price TargetBuy$209.00 ➝ $218.00Low
i
4/30/2020JPMorgan Chase & Co.Boost Price Target$149.00 ➝ $188.00Medium
i
4/30/2020Morgan StanleyBoost Price TargetOverweight$172.00 ➝ $241.00Medium
i
4/30/2020Bank of AmericaBoost Price TargetNeutral$147.00 ➝ $190.00Medium
i
4/29/2020KeyCorpDowngradeOverweight ➝ Sector WeightMedium
i
4/27/2020Wolfe ResearchUpgradeUnderperform ➝ Market Perform$188.00Medium
i
4/27/2020CitigroupUpgradeNeutral ➝ Buy$204.00 ➝ $214.00High
i
4/23/2020BarclaysBoost Price TargetOverweight$188.00 ➝ $195.00Medium
i
4/16/2020MizuhoLower Price TargetNeutral$163.00 ➝ $158.00Medium
i
4/13/2020SunTrust BanksLower Price TargetBuy$225.00 ➝ $200.00Medium
i
4/8/2020Morgan StanleyLower Price TargetOverweight$211.00 ➝ $172.00High
i
4/2/2020JPMorgan Chase & Co.Lower Price TargetOverweight$182.00 ➝ $149.00Medium
i
3/30/2020Wells Fargo & CompanyLower Price TargetOverweight$215.00 ➝ $170.00Medium
i
3/30/2020KeyCorpLower Price TargetOverweight$212.00 ➝ $170.00High
i
3/26/2020BarclaysLower Price TargetOverweight$212.00 ➝ $188.00Low
i
3/24/2020JPMorgan Chase & Co.Lower Price TargetOverweight$204.00 ➝ $182.00High
i
2/25/2020MizuhoBoost Price TargetNeutral$174.00 ➝ $190.00High
i
2/18/2020Morgan StanleyBoost Price TargetOverweight$199.00 ➝ $211.00Medium
i
Rating by Ricky Goldwasser at Morgan Stanley
2/14/2020Evercore ISIInitiated CoverageBuy$215.00Medium
i
Rating by Michael Newshel at Evercore ISI
2/14/2020CitigroupBoost Price TargetNeutral$179.00 ➝ $204.00Low
i
2/13/2020Piper SandlerBoost Price Target$177.00 ➝ $219.00Low
i
1/7/2020Wells Fargo & CompanyInitiated CoverageOverweight$210.00High
i
1/3/2020Bank of AmericaDowngradeNeutral ➝ UnderperformLow
i
10/24/2019Canaccord GenuityReiterated RatingHold$170.00Low
i
10/21/2019UBS GroupLower Price TargetBuy$204.00 ➝ $200.00Low
i
8/23/2019Morgan StanleyBoost Price TargetOverweight$190.00 ➝ $201.00Medium
i
Rating by Ricky Goldwasser at Morgan Stanley
8/8/2019KeyCorpBoost Price TargetOverweight$172.00 ➝ $192.00Medium
i
7/26/2019Morgan StanleyBoost Price TargetOverweight$175.00 ➝ $190.00High
i
Rating by Ricky Goldwasser at Morgan Stanley
7/16/2019Bank of AmericaUpgradeUnderperform ➝ Neutral$174.60Low
i
7/15/2019BarclaysSet Price TargetBuy$200.00Low
i
Rating by Jack Meehan at Barclays PLC
6/20/2019Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$180.00 ➝ $220.00High
i
5/20/2019MizuhoBoost Price TargetNeutral$150.00 ➝ $174.00Low
i
5/2/2019Canaccord GenuityBoost Price TargetHold ➝ Hold$155.00 ➝ $165.00Low
i
5/1/2019CitigroupBoost Price TargetNeutral ➝ Neutral$157.00 ➝ $176.00Low
i
5/1/2019UBS GroupBoost Price TargetBuy ➝ Buy$178.00 ➝ $195.00Low
i
Rating by Kevin Caliendo at UBS Group AG
4/2/2019Wolfe ResearchInitiated CoverageUnderperformLow
i
4/2/2019Jefferies Financial GroupUpgradeHold ➝ Buy$154.00 ➝ $190.00Medium
i
3/18/2019BarclaysBoost Price TargetOverweight ➝ Overweight$165.00 ➝ $173.00Low
i
2/27/2019Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$160.00 ➝ $164.00Low
i
2/22/2019Morgan StanleySet Price TargetBuy$175.00Low
i
Rating by Ricky Goldwasser at Morgan Stanley
2/8/2019UBS GroupSet Price TargetBuy$178.00Low
i
Rating by Kevin Caliendo at UBS Group AG
1/17/2019UBS GroupInitiated CoverageBuy ➝ Buy$169.00High
i
1/3/2019Bank of AmericaDowngradeNeutral ➝ UnderperformMedium
i
12/20/2018Morgan StanleySet Price TargetBuy$177.00Medium
i
Rating by Ricky Goldwasser at Morgan Stanley
12/9/2018The Goldman Sachs GroupLower Price Target$190.00 ➝ $180.00Low
i
Rating by Patrick B Donnelly at The Goldman Sachs Group, Inc.
12/9/2018Morgan StanleyLower Price Target$202.00 ➝ $180.00Low
i
Rating by Ricky Goldwasser at Morgan Stanley
12/6/2018KeyCorpLower Price TargetOverweight ➝ Overweight$210.00 ➝ $165.00Low
i
12/3/2018SunTrust BanksLower Price TargetBuy$175.00Low
i
12/3/2018BarclaysLower Price TargetOverweight ➝ Overweight$205.00 ➝ $165.00Medium
i
12/3/2018CitigroupLower Price TargetNeutral ➝ Neutral$171.00 ➝ $160.00Medium
i
12/3/2018William BlairReiterated RatingBuyMedium
i
Rating by Matt Larew at William Blair
12/3/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$202.00 ➝ $180.00Medium
i
Rating by Ricky Goldwasser at Morgan Stanley
12/3/2018Bank of AmericaDowngradeBuy ➝ NeutralMedium
i
12/3/2018Craig HallumDowngradeBuy ➝ HoldMedium
i
12/2/2018Canaccord GenuityReiterated RatingHold ➝ Hold$162.00 ➝ $155.00Medium
i
12/2/2018The Goldman Sachs GroupLower Price Target$190.00Medium
i
11/30/2018The Goldman Sachs GroupDowngradeConviction-Buy ➝ Buy$190.00 ➝ $180.00High
i
10/30/2018ArgusDowngradeBuy ➝ HoldLow
i
10/25/2018Robert W. BairdLower Price TargetOutperform$205.00 ➝ $190.00Low
i
Rating by Eric Coldwell at Robert W. Baird
10/25/2018CitigroupLower Price TargetNeutral$184.00 ➝ $171.00Low
i
10/25/2018MizuhoSet Price TargetHold$169.00Low
i
Rating by Ann Hynes at Mizuho
10/25/2018Canaccord GenuityDowngradeBuy ➝ Hold$190.00 ➝ $162.00Low
i
10/24/2018William BlairReiterated RatingOutperformMedium
i
Rating by M. Larew at William Blair
10/19/2018Bank of AmericaInitiated CoverageBuy ➝ BuyLow
i
10/3/2018Craig HallumLower Price TargetBuy$201.00 ➝ $193.00Low
i
9/19/2018MizuhoReiterated RatingNeutralLow
i
Rating by A. Hynes at Mizuho
9/10/2018Morgan StanleyBoost Price TargetOverweight ➝ Buy$192.00 ➝ $202.00Low
i
9/4/2018Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$197.00 ➝ $195.00Medium
i
8/22/2018ArgusReiterated RatingBuyLow
i
8/20/2018Deutsche Bank AktiengesellschaftLower Price TargetHold ➝ Hold$195.00 ➝ $190.00Medium
i
Rating by Dan Leonard at Deutsche Bank Aktiengesellschaft
7/26/2018MizuhoReiterated RatingHold$189.00Low
i
Rating by Ann Hynes at Mizuho
7/26/2018Jefferies Financial GroupReiterated RatingHold ➝ Neutral$180.00Low
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
7/24/2018Canaccord GenuityReiterated RatingBuy$200.00High
i
7/20/2018SunTrust BanksReiterated RatingBuy$220.00Low
i
6/27/2018Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$172.00Medium
i
6/7/2018KeyCorpUpgradeSector Weight ➝ Overweight$210.00Low
i
5/25/2018BarclaysBoost Price TargetEqual Weight ➝ Overweight$210.00 ➝ $220.00High
i
5/25/2018MizuhoReiterated RatingHoldHigh
i
Rating by Ann Hynes at Mizuho
5/1/2018Robert W. BairdUpgradeNeutral ➝ Outperform$183.00 ➝ $203.00Low
i
Rating by Eric Coldwell at Robert W. Baird
3/23/2018ArgusInitiated CoverageBuy$202.00High
i
3/8/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$192.00 ➝ $195.00Low
i
3/6/2018Jefferies Financial GroupReiterated RatingHold$176.00Medium
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
3/1/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$190.00 ➝ $192.00Medium
i
2/28/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$182.00 ➝ $192.00Medium
i
2/28/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$190.00 ➝ $195.00Medium
i
2/26/2018BarclaysBoost Price TargetOverweight ➝ Overweight$195.00 ➝ $210.00Medium
i
2/9/2018CitigroupBoost Price TargetNeutral ➝ Neutral$161.00 ➝ $184.00Medium
i
2/8/2018Robert W. BairdSet Price TargetNeutral ➝ Hold$150.00 ➝ $183.00High
i
Rating by Whit Mayo at Robert W. Baird
2/7/2018Craig HallumReiterated RatingBuy$180.00 ➝ $204.00Low
i
1/29/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Buy$128.00 ➝ $205.00Low
i
1/24/2018MizuhoSet Price TargetHold$178.00Low
i
Rating by Ann Hynes at Mizuho
1/4/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$176.00High
i
12/13/2017BarclaysReiterated RatingBuy$195.00Low
i
12/1/2017MizuhoSet Price TargetNeutral ➝ Neutral$160.00 ➝ $165.00Medium
i
Rating by Ann Hynes at Mizuho
11/24/2017Jefferies Financial GroupSet Price TargetHold$167.00Low
i
10/27/2017Robert W. BairdReiterated RatingHold$150.00N/A
i
10/26/2017BarclaysBoost Price TargetOverweight$183.00 ➝ $190.00N/A
i
10/26/2017Deutsche Bank AktiengesellschaftBoost Price TargetBuy$170.00 ➝ $172.00N/A
i
10/26/2017Craig HallumReiterated RatingBuy$175.00 ➝ $180.00N/A
i
10/20/2017Jefferies Financial GroupReiterated RatingHold$170.00N/A
i
10/17/2017Robert W. BairdReiterated RatingHold$166.00N/A
i
10/12/2017SunTrust BanksReiterated RatingBuy$190.00N/A
i
10/12/2017Wells Fargo & CompanyInitiated CoverageMarket Perform ➝ Outperform$175.00N/A
i
9/26/2017KeyCorpReiterated RatingHoldLow
i
9/17/2017Robert W. BairdReiterated RatingNeutral ➝ HoldLow
i
9/13/2017Jefferies Financial GroupReiterated RatingHold$157.00 ➝ $170.00Medium
i
9/11/2017Canaccord GenuityReiterated RatingBuy$175.00 ➝ $180.00Medium
i
8/10/2017Morgan StanleyBoost Price TargetOverweight$154.00 ➝ $166.00Low
i
7/27/2017BarclaysBoost Price TargetOverweight$182.00 ➝ $183.00Low
i
Rating by Jack Meehan at Barclays PLC
7/27/2017Craig HallumReiterated RatingBuy$157.00 ➝ $179.00Medium
i
7/17/2017BarclaysReiterated RatingOverweight$175.00 ➝ $182.00Low
i
Rating by Jack Meehan at Barclays PLC
7/13/2017Credit Suisse GroupDowngradeHold$146.00Low
i
5/28/2017Credit Suisse GroupReiterated RatingBuy$146.00Medium
i
4/28/2017Jefferies Financial GroupLower Price TargetHold$159.00 ➝ $157.00Low
i
3/7/2017BarclaysBoost Price TargetOverweight ➝ Overweight$165.00 ➝ $175.00N/A
i
Rating by Jack Meehan at Barclays PLC
2/18/2017BarclaysSet Price TargetBuy$165.00N/A
i
Rating by Jack Meehan at Barclays PLC
2/17/2017Jefferies Financial GroupReiterated RatingHold$159.00N/A
i
2/17/2017Canaccord GenuityBoost Price TargetBuy$140.00 ➝ $150.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
2/17/2017MizuhoBoost Price TargetNeutral$135.00 ➝ $139.00N/A
i
2/6/2017Robert W. BairdDowngradeOutperform ➝ Neutral$138.00N/A
i
1/23/2017Canaccord GenuitySet Price TargetBuy$140.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
1/18/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy$170.00N/A
i
1/17/2017Canaccord GenuitySet Price TargetBuy$140.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
10/30/2016Canaccord GenuitySet Price TargetBuy$140.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
10/25/2016GabelliInitiated CoverageBuy$180.00N/A
i
Rating by S. Wojda at Gabelli
9/15/2016MizuhoBoost Price TargetNeutral$132.00 ➝ $145.00N/A
i
9/14/2016Canaccord GenuitySet Price TargetBuy$155.00N/A
i
Rating by mark massaro at Canaccord Genuity
9/9/2016CitigroupInitiated CoverageNeutral$156.00N/A
i
8/29/2016BarclaysSet Price TargetBuy$155.00N/A
i
8/16/2016KeyCorpBoost Price TargetOverweight$143.00 ➝ $150.00N/A
i
Rating by Donald Hooker at KeyCorp
7/28/2016SunTrust BanksReiterated RatingBuyN/A
i
Rating by David S Macdonald at SunTrust Banks, Inc.
7/28/2016Canaccord GenuitySet Price TargetBuy$155.00N/A
i
Rating by Mark Massaro at Canaccord Genuity
7/28/2016UBS GroupBoost Price TargetNeutral$125.00 ➝ $137.50N/A
i
7/27/2016Evercore ISIBoost Price TargetBuy$147.00 ➝ $155.00N/A
i
(Data available from 6/16/2016 forward)
Laboratory Co. of America logo
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Read More

Today's Range

Now: $259.09
$258.00
$260.81

50 Day Range

MA: $266.26
$252.02
$278.14

52 Week Range

Now: $259.09
$155.65
$280.69

Volume

551,628 shs

Average Volume

705,304 shs

Market Capitalization

$25.31 billion

P/E Ratio

9.63

Dividend Yield

N/A

Beta

1.04

Frequently Asked Questions

What sell-side analysts currently cover shares of Laboratory Co. of America?

The following sell-side analysts have issued stock ratings on Laboratory Co. of America in the last year: Argus, Bank of America Co., Citigroup Inc., Deutsche Bank Aktiengesellschaft, Jefferies Financial Group Inc., JPMorgan Chase & Co., Mizuho, SunTrust Banks, Inc., TheStreet, Truist, Truist Securities, Wells Fargo & Company, William Blair, Wolfe Research, and Zacks Investment Research.
View the latest analyst ratings for LH.

What is the current price target for Laboratory Co. of America?

12 Wall Street analysts have set twelve-month price targets for Laboratory Co. of America in the last year. Their average twelve-month price target is $276.08, suggesting a possible upside of 6.2%. Truist has the highest price target set, predicting LH will reach $320.00 in the next twelve months. Wolfe Research has the lowest price target set, forecasting a price of $217.00 for Laboratory Co. of America in the next year.
View the latest price targets for LH.

What is the current consensus analyst rating for Laboratory Co. of America?

Laboratory Co. of America currently has 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LH will outperform the market and that investors should add to their positions of Laboratory Co. of America.
View the latest ratings for LH.

What other companies compete with Laboratory Co. of America?

Other companies that are similar to Laboratory Co. of America include Quest Diagnostics, DaVita, Amedisys, Chemed, LHC Group, R1 RCM, AMN Healthcare Services, MEDNAX, CorVel, Tivity Health and Cross Country Healthcare.

How do I contact Laboratory Co. of America's investor relations team?

Laboratory Co. of America's physical mailing address is 358 South Main Street, BURLINGTON NC, 27215. The medical research company's listed phone number is 336-229-1127 and its investor relations email address is [email protected] The official website for Laboratory Co. of America is www.labcorp.com.